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Abstract – A targeted, stimuli-responsive, polymeric 
drug delivery vehicle is being developed in our lab to 
help alleviate severe side-effects caused by narrow 
therapeutic window drugs.  Targeting specific cell 
types or organs via proteins, specifically, lectin-
mediated targeting holds potential due to the high 
specificity and affinity of receptor-ligand interactions, 
rapid internalization, and relative ease of processing. 
 
Dextran, a commercially available, biodegradable 
polymer has been conjugated to doxorubicin and 
galactosamine to target hepatocytes in a three-step, 
one-pot synthesis.  The loading of doxorubicin and 
galactose on the conjugates was determined by 
absorbance at 485 nm and elemental analysis, 
respectively.  Conjugation efficiency based on the 
amount loaded of each reactant varies from 20% to 
50% for doxorubicin and from 2% to 20% for 
galactosamine.  Doxorubicin has also been attached to 
dextran through an acid-labile hydrazide bond. 
 
Doxorubicin acts by intercalating with DNA in the 
nuclei of cells.  The fluorescence of doxorubicin is 
quenched when it binds to DNA.  This allows a 
fluorescence-based cell-free assay to evaluate the 
efficacy of the polymer conjugates where we measure 
the fluorescence of doxorubicin and the conjugates in 
increasing concentrations of calf thymus DNA.  
Fluorescence quenching indicates that our conjugates 
can bind to DNA.  The degree of binding increases 
with polymer molecular weight and substitution of 
doxorubicin.  
 
In cell culture experiments with hepatocytes, the 
relative uptake of polymer conjugates was evaluated 
using flow cytometry, and the killing efficiency was 
determined using the MTT cell proliferation assay.  
We have found that conjugate uptake is much lower 
than that of free doxorubicin.  Lower uptake of 
conjugates may increase the maximum dose of drug 
tolerated by the body.  Also, non-galactosylated 
conjugate uptake is lower than that of the 
galactosylated conjugate.  Microscopy indicates that 
doxorubicin localizes almost exclusively at the 
nucleus, whereas the conjugates are present 
throughout the cell.  Doxorubicin linked to dextran 
through a hydrazide bond was used to achieve 
improved killing efficiency.  Following uptake, the 
doxorubicin dissociates from the polymer in an 
endosomal compartment and diffuses to the nucleus.  
The LC50 of covalently linked doxorubicin is 7.4 
µg/mL, whereas that of hydrazide linked doxorubicin 
is 4.4 µg/mL.  
 
